Investing.com -- Viridian Therapeutics, Inc. (NASDAQ: VRDN) reported a narrower-than-expected first quarter loss on Tuesday, but shares fell 4.5% as investors focused on the company’s ongoing clinical ...

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today ...